These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9436641)

  • 1. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
    Szepeshazi K; Schally AV; Nagy A; Halmos G; Groot K
    Anticancer Drugs; 1997 Nov; 8(10):974-87. PubMed ID: 9436641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs.
    Szepeshazi K; Schally AV; Nagy A
    Breast Cancer Res Treat; 1999 Aug; 56(3):267-76. PubMed ID: 10573117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
    Szepeshazi K; Schally AV; Halmos G; Szoke B; Groot K; Nagy A
    Breast Cancer Res Treat; 1996; 40(2):129-39. PubMed ID: 8879679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Breast Cancer Res Treat; 2000 Feb; 59(3):255-62. PubMed ID: 10832595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
    Nagy A; Schally AV; Armatis P; Szepeshazi K; Halmos G; Kovacs M; Zarandi M; Groot K; Miyazaki M; Jungwirth A; Horvath J
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7269-73. PubMed ID: 8692981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo.
    Szepeshazi K; Schally AV; Juhasz A; Nagy A; Janaky T
    Anticancer Drugs; 1992 Apr; 3(2):109-16. PubMed ID: 1388062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
    Milovanovic SR; Monje E; Szepeshazi K; Radulovic S; Schally A
    J Cancer Res Clin Oncol; 1993; 119(5):273-8. PubMed ID: 8382705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
    Milovanovic SR; Radulovic S; Schally AV
    Breast Cancer Res Treat; 1992; 24(2):147-58. PubMed ID: 8443402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
    Szepeshazi K; Schally AV; Halmos G
    Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
    Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
    J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
    Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
    Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
    Koppán M; Nagy A; Schally AV; Plonowski A; Halmos G; Arencibia JM; Groot K
    Prostate; 1999 Feb; 38(2):151-8. PubMed ID: 9973101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].
    Szepeshazi K; Schally AV; Keller G; Block NL; Benten D; Halmos G; Szalontay L; Vidaurre I; Jaszberenyi M; Rick FG
    Oncotarget; 2012 Jul; 3(7):686-99. PubMed ID: 22824624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.
    Halmos G; Nagy A; Lamharzi N; Schally AV
    Cancer Lett; 1999 Mar; 136(2):129-36. PubMed ID: 10355741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
    Kovacs M; Schally AV; Nagy A; Koppan M; Groot K
    Proc Natl Acad Sci U S A; 1997 Feb; 94(4):1420-5. PubMed ID: 9037068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.